Forbion, a venture capital firm, led a $35m Series B funding round in ARMGO Pharma, a biopharmaceutical company, with participation from Pontifax and Kurma Partners. “We are pleased to have Forbion leading this financing round alongside Pontifax and Kurma Partners. They are all experienced healthcare investors that see the potential of ARMGO’s approach to provide disease-modifying treatments for patients by restoring the physiological Ca2+ homeostasis in affected tissues. We are excited to drive development of ARM210 in multiple indications and for the potential to reach significant milestone achievements within the next two years,” Gene Marcantonio, ARMGO President and Chief Medical Officer.